Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
Shares of Protalix BioTherapeutics (AMEX:PLX) were gapping down Friday morning with an open price 15.6% lower than Thursday's closing price. The stock closed at $6.60 yesterday and opened today's trading at $5.57.
NEW YORK ( TheStreet) -- Shares of Protalix BioTherapeutics (AMEX: PLX) were gapping down Friday morning with an open price 15.6% lower than Thursday's closing price. The stock closed at $6.60 Thursday and opened today's trading at $5.57.
The average volume for Protalix BioTherapeutics has been 887,500 shares per day over the past 30 days. Protalix BioTherapeutics has a market cap of $623 million and is part of the health care sector and drugs industry. Shares are up 37.5% year to date as of the close of trading on Thursday. Protalix BioTherapeutics, Inc., a biopharmaceutical company, through Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. The company has a P/E ratio of 15.4, below the average drugs industry P/E ratio of 15.8 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Protalix BioTherapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. You can view the full Protalix BioTherapeutics Ratings Report. Get more investment ideas from our investment research center.